UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...

Medscape Medical News, November 25, 2024 ACR 2024 Dapirolizumab Cuts Disease Activity, Steroid Use in SLE Half of lupus patients taking dapirolizumab pegol achieved response at week 48 compared ...